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Abstract  
The main Hypertension in the Very Elderly Trial (HYVET) demonstrated a very marked 
reduction in cardiovascular events by treating hypertensive participants  80 years or older 
with a low dose, sustained release prescription of indapamide (indapamide SR, 1.5 mg) to 
which was added a low dose of an angiotensin converting enzyme inhibitor in two thirds of 
cases (perindopril 2-4 mg). This report from the Ambulatory Blood Pressure Sub-study 
investigates whether changes in arterial stiffness and ambulatory blood pressure could both 
explain the benefits observed in the main trial. 139 participants were randomised to placebo 
[67] and to active treatment [72] and had both day and night observations of blood pressure 
and arterial stiffness as determined from the QKD interval. The QKD interval was 5.6 ms 
longer (P= 0.017) in the actively treated group at night than in the placebo group. This was 
not true for the more numerous day-time readings so that 24hr results were similar in the 2 
groups. The QKD interval remained longer at night in the actively treated group even when 
adjusted for systolic pressure, heart rate and height.  The reduced arterial stiffness at night 
may partly explain the marked benefits observed in the main trial. 
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Introduction 
Arterial stiffness is associated with an increase in blood pressure (BP). Greater stiffness has 
also been shown to be related to an increase in cardiovascular events, independent of blood 
pressure. [1, 2] There is evidence that thiazide diuretics have little effect on arterial stiffness 
[3] but little is known of the effects of non-thiazide diuretics such as indapamide and 
chlorthalidone. Angiotensin Converting Enzyme inhibitors (ACE-I) reduce arterial stiffness 
and, in one randomized trial, the combination of perindopril (an ACE-I) and indapamide 
reduced augmentation index (AI x) compared to atenolol but not arterial pulse wave velocity 
(A-PWV). [4]  
The lack of effect on A-PWV may have been due to atenolol also reducing A-PWV.[4-6] In 
the Hypertension in the Very Elderly Trial (HYVET) the effect on 24 hour BP and arterial 
stiffness with indapamide and perindopril was compared with matched placebo in very elderly 
(more than or equal to 80 years) hypertensive subjects. [7] A measure of arterial stiffness, the 
QKD interval (time interval between the QRS wave on the electrocardiogram (ECG) and the 
detection of the last Korotkoff sound during BP measurement over the brachial artery) is 
closely related to A-PWV [8] and was explored in a 24 hour ambulatory blood pressure sub-
study. [9] Since QKD measures the time taken for the pulse wave to travel from the heart to 
the recording point, it is negatively correlated with the velocity as given by PWV and is also 
negatively correlated with arterial stiffness. This means that a higher QKD is associated with 
a lower arterial stiffness and vice versa. The results of the sub-study provided information on 
the effects of indapamide + perindopril on arterial stiffness and its circadian variation. 
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Method 
The protocol for Ambulatory Blood Pressure (ABP) and QKD monitoring in HYVET has 
been published elsewhere, [9] as has the protocol for the main study (registered trial number 
NCT00122811) and the main results. [10] Participants were eligible for the trial if they were 
aged >=80 years and had an average systolic clinic blood pressure (CBP) of 160 to 199 mm 
Hg after at least a 2-month placebo single blind run-in and an average standing systolic CBP 
of >140 mm Hg. At the start of the trial, the participants had to have a diastolic CBP of 90 to 
109 mm Hg, although this criterion was later relaxed to allow the inclusion of subjects with 
isolated systolic hypertension and diastolic clinic CBP<90 mm Hg. Treatment was started 
with indapamide sustained release (SR) 1.5 mg daily or matching placebo, to which could be 
added perindopril 2 or 4 mg daily (or matching placebo) to achieve a goal of systolic CBP 
<150 mm Hg and diastolic CBP <80mm Hg.  
 
ABP readings were recorded by the validated Diasys Integra II ABP recording machine. [11-
12] This machine recorded auscultatory readings if possible and oscillometric readings when 
the auscultatory readings were not satisfactory. Auscultatory readings were recorded in 86% 
of instances. The Diasys Integra II also measures arterial stiffness using the QKD interval 
[13] and relies on auscultatory readings for this measure. The reproducibility of QKD 
measurements has been reported to be satisfactory. [14] This machine was selected as it 
provides a 24hr measure that includes the cardiac pre-ejection period and, most importantly, a 
transit time related inversely to pulse wave velocity. 
 
It was planned to recruit 600 patients into the substudy with data both at baseline and during 
the double-blind phase of the trial. Unfortunately, this was not achieved, though 284 were 
recruited. Of these, 36 were excluded for the following reasons: 11 recorded <60% of possible 
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auscultatory readings, 3 were studied while no longer on trial medication, and 1 was excluded 
because of uncontrolled atrial tachycardia. For baseline measurements, 7 were excluded 
because they were studied within 7 days of starting placebo run-in and were previously on 
antihypertensive treatment; and 14 were studied after randomization and may have started 
trial medication. This left 248 patients in the sub-study (112 studied at baseline and 186 on 
double-blind treatment after about 1 year). The communication considers the 186 studied on 
treatment (or placebo). Of these, 139 had both day and night-time readings recorded and 
allowed the investigation of circadian rhythm (67 on placebo and 72 on active treatment). The 
required number of readings in each period and other quality control issues were previously 
described. [9] Baseline measurements of QKD were only available in 50 participants who had 
measurements during treatment and therefore adjustment was not made for baseline values. 
Daytime ambulatory readings were those recorded between 8:00am and 8:00pm. (The time 
8:00pm was chosen because some elderly participants retire to bed early.) Night time readings 
were recorded between 10:00pm and 6:00am. (The time 6:00am was chosen in view of the 
tendency in the very elderly to sleep a shorter number of hours.) 
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Statistical methods 
The QKD data were analysed using linear mixed models. These models are useful where 
repeated measurements are made on the same subject, as in this study, and have the advantage 
of dealing with missing values. Subject was treated as a random effect, and treatment (active 
or placebo), and time of day (day or night) were fixed effects. An interaction term treatment* 
multiplied by day-night difference was included to determine if treatment influenced the 
circadian rhythm of QKD. Systolic BP, heart rate and height are known to be associated with 
QKD and were therefore also included in the model. The analysis was carried out using 
SAS/STAT software (SAS Institute Inc., Cary, NC, USA). P values less than 0.05 were 
deemed to indicate statistical significance. 
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Results 
Of the 67 participants receiving a placebo, 69% were female and their average age was 84±3 
years. Similarly of the 72 receiving active treatment 64% were female and their average age 
was 84±6 years. Height ranged from 145 cm to 183 cm (mean 161 cm) in those given placebo 
and 138 cm to 185 cm (mean 160 cm) in those randomized to active treatment. 
Table 1 gives the results after an average of 13 months placebo or active treatment. Both 
ambulatory systolic and diastolic BP were lower at night than during the day (by an average 
of 10mm Hg systolic and 6mm Hg diastolic pressure). Systolic BP was lower on active 
treatment than placebo by an average of 8mm Hg systolic and 6mm Hg diastolic. Heart rate 
was lower by night than during the day by an average of 9 beats per minute. QKD was similar 
in placebo and active treated groups during the day but QKD was higher at night on active 
treatment compared with placebo by 5.6 ms. 
Figure 1 gives the ambulatory systolic BP according to treatment group. The lower BP at 
night is clearly shown for both treatment groups as is the post prandial dip, which was marked 
in these very elderly hypertensive patients, averaging 11 mm Hg between the morning peak at 
09:00 and 14:00 hours. Figure 2 gives the 24hr heart rate results, indicating a higher heart rate 
in the placebo group at night. Figure 3 illustrates the 24 hour QKD results and shows the 
higher average QKD results at night in the active treatment group. Figure 4 confirms these 
results after adjustments for systolic BP, heart rate and height. The mixed model results 
(Table 2) showed the importance of adjusting for systolic BP (p< 0.001), height (P=0.006) 
and possibly heart rate (p=0.089).  QKD also varied between day and night (p=0.002) being 
longer at night. Although no significant overall effect of treatment was found, there was a 
significant interaction between day-night and treatment (p=0.017), independent of other 
variables, suggesting that the difference between treatments depends on whether it is day or 
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night and supporting the finding of a longer QKD (lower stiffness) at night in the actively 
treated group. 
 
Discussion  
Over the 24 hour period, QKD and therefore arterial stiffness were similar in the actively and 
placebo treated groups. However, there was a marked circadian rhythm with higher stiffness 
(lower QKD) during the day. The QKD (uncorrected for systolic BP and heart rate) was 
longer in the actively treated group at night (Figure 3). A higher QKD may be driven by a 
lower systolic BP and heart rate. However correction for these factors (figure 4) did not 
remove this effect and the statistical model demonstrated a difference in circadian rhythm 
between the 2 treatment groups (P=0.017) with higher adjusted QKD at night in the actively 
treated group balanced by a slightly lower adjusted QKD during the day. 
Which is the better predictor of cardiovascular events, a higher arterial stiffness during the 
daytime or at night? With respect to BP, a recent meta-analysis concluded that a higher night-
time BP is a better predictor for adverse outcome than a higher day-time BP or even a low 
day-night BP ratio. [15] Specifically a high night-time BP rather than day-time BP is 
associated with chronic kidney disease, [16] left ventricular hypertrophy [17] and 
cardiovascular disease. [18-20]  
Cuspidi and Grassi [21] conclude that nocturnal BP should be targeted by treatment.  
In the actively treated group, systolic BP was 8/5 mm Hg lower at night and pulse rate 1.4 
beats per minute lower than in the placebo group. However this could not explain the higher 
QKD at night of 5.6 ms in the actively treated group. QKD was not closely related to BP and 
although figure 2 and 3 show a good inverse relation between QKD and heart rate, figures 1 
and 3 do not show such a clear relation between QKD and BP, the dip in BP between 10:00 
and 15:00 hours not being associated with any change in QKD. Moreover during the day BP 
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was 8/7 mm Hg lower in the actively treated group but QKD tended to average 1.5 ms lower. 
Finally adjustments for systolic BP did not negate the prolonged QKD at night in the active 
group (figure 4). We conclude that indapamide + perindopril favourably affected arterial 
compliance at night independently from BP. 
As reducing BP at night is especially beneficial it is possible that lowering arterial compliance 
at night produces extra benefits. This possibility is underlined by the very positive results of 
the main HYVET trial. [10] As two thirds of the participants in the HYVET trial had both 
indapamide and perindopril it is not possible to ascribe the potential benefits to one drug or 
the other. The combination has been shown to reduce A-PWV (4) although one study claimed 
that neither a thiazide nor an ACE inhibitor reduces PWV (5). A further study claimed that an 
ACE inhibitor could reduce brachial-radial PWV by 17% [22] and the possibility that ACE 
inhibitors increase large artery compliance is supported by many authors. [23-28] 
PWV is a measure of arterial stiffness and it is considered that aortic PWV (Ao-PWV) is the 
most important measure. [25] In contrast augmentation index is thought to be a surrogate for 
the stiffness of arterioles. [3] The QKD measures aortic and brachial PWV, and includes the 
pre-ejection period (PEP). Aortic PWV reflects arterial stiffness in the elderly owing to the 
marked increase in arterial PWV with age. [29-30] Ao-PWV is an established independent 
predictor of cardiovascular events and deaths, and coronary heart disease and stroke. 
[1,2,23,31-32] It is therefore probable that a prolongation of QKD at night reflects a reduction 
in Ao-PWV and an important benefit of treatment over and above clinic blood pressure 
reduction. [32]  
It was very interesting that the circadian rhythm for QKD did not reflect that of ABP. This 
reinforces the concept that that Ao-PWV is not synonymous with brachial BP and provides 
additional information.  In fact the circadian rhythm of QKD was most closely aligned to that 
of heart rate. The inverse relationship between heart rate and arterial compliance has also been 
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reported in the AMCap Study. [33] Cremer et al [32] have suggested that QKD may be 
employed, with mean brachial systolic BP, heart rate and height, to measure central systolic 
BP, as a reduction in central BP is associated with better outcome. [33] It is possible that the 
combination of indapamide and perindopril produces benefits from either lowering Ao-PWV 
or central pressure or both. 
The AmCAP study [33] also revealed that central pressure is relatively higher than brachial 
pressure at night. Thus a reduction in central pressure at night may explain why nocturnal 
blood pressure is so good a predictor of cardiovascular events.  
 
The strengths of the sub-study are in the description of the circadian rhythm of QKD with 
control for BP, height and heart rate. The limitations of the study include the failure to 
provide baseline to treatment changes, the extrapolation of measurements of QKD to arterial 
PWV and, although a large study for an arterial compliance trial, failure to include the 
intended number of participants. The QKD interval consists of the pre-ejection period (PEP) 
plus the pulse transit time (PTT). Changes in the former, rather than the latter could have 
explained the results. However, although PEP may be prolonged by an increase in BP, this is 
thought to be due to chronic hypertension increasing electromechanical delay [34] which is 
unlikely to occur in the short term. Moreover, adjustment for BP did not alter our results and 
our results could only be explained by an increase in PEP whereas a decrease would be 
expected. Similarly a reduction in pre-load could prolong PEP. This could occur at night as a 
diuretic can increase PEP. [35] However, the QKD was prolonged even after adjustment for a 
lower BP, and the dose of indapamide employed was unlikely to produce a diuresis.   
In conclusion, the marked reduction in cardiovascular events, and the rise in QKD at night in 
the HYVET trial suggests further investigation of the changes in the circadian rhythm of 
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arterial compliance with indapamide, chlorthalidone, a thiazide diuretic, an ACE inhibitor, a 
calcium channel blocker and other comparators.  
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Table 1. Means (standard deviations) after an average of 13 months placebo or active 
treatment.  
QKD: Q wave korotkoff diastolic time interval in milliseconds (ms). BP: blood pressure. 
  Placebo Active P value Placebo Active P value 
n 
 
 
Day 
       72 
     Day 
 67 
Night 
72 
Night 
 
QKD (ms) 180.7(20.7) 179.2 (21.1) 0.67 188.0(19.5) 193.6 (26.5) 0.16 
Systolic BP 
(mm.Hg) 
127.7 (16.4) 119.8 (14.0) <0.01 117.4 (19.9) 109.9 (14.5) 0.01 
Diastolic BP 
(mm.Hg) 
79.1 (11.3) 72.6 (8.3) <0.01 71.8 (11.7) 66.6 (9.0) <0.01 
Pulse pressure 
(mm.Hg) 
48.6 (13.8) 47.3 (12.2) 0.56 45.6 (14.7) 43.3 (12.5) 0.32 
Heart rate 
Beats/min) 
73.8 (9.1) 75.2 (9.0) 0.36 66.3 (8.1) 64.9 (8.8) 0.33 
 
 
 
 
 
Table 2. Summary results from the normal mixed model analysis, outcome variable = QKD 
(ms): Q wave korotkoff diastolic interval. 
 
Predictor Coefficient Standard Error t Value P 
Intercept 176 31.1 5.66 <.001 
Treatment (Placebo)  -2.39 3.56 -0.67 0.503 
Day-Night (Day) -7.70 2.47 -3.12 0.002 
Treatment*Day-Night 6.57 2.72 2.41 0.017 
Systolic BP -0.416 0.0756 -5.50 <.001 
Heart rate -0.248 0.145 -1.71 0.089 
Height (m) 0.495 0.177 2.80 0.006 
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Figure 1. Ambulatory systolic blood pressure according to treatment group. 
 
 
 
 
 
 
Figure 2. Heart rate according to treatment group. 
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Figure 3. QKD (Q wave korotkoff diastolic interval) according to treatment group. 
 
 
 
 
 
 
Figure 4 QKD (Q wave korotkoff diastolic interval) adjusted for systolic blood pressure, heart 
rate, and height, according to treatment group. 
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Appendix  
HYVET Principal Investigation: C.J.Bulpitt Co-investigation: A.E.Fletcher 
 
HYVET Committees: Streering Committee: T. McCormack, J.Potter, B.G Extremera, P. 
Sever, F. Forette, D. Dumitrascu, C. Swift, J. Tuomilehto, J. Coope (retired in 2001), C. 
Nachev (deceased); Data Monitoring Committee: J.A.Staessen, L Thijs, R. Clarke, K. 
Narkiewicz; End Points Committee: C. Davidson (retired in 2003), J. Duggan, G. Leonetti, 
N. Gainsborough, M.C. De Vernejoul, J.Wang, V. Stoyanovsky; Ethics Committee: R. 
Fagard, J. Grimley Evans, B. Williams; ABPM Sub-Study Committee: C. Rajkumar, J.A. 
Staessen, C.J. Bulpitt 
 
Centres participating in the ABP side project were: 
Bulgaria: V. Gergova; Sofia: C. Nachev (deceased); Sofia: V. Stoyanovsky: Sofia. 
China: J. Wang; Shanghai: S. Wang; Beijing: GE Yaun; Beijing; W. Zhang; Shanghai: 
Finland: H. Litmanen; Kuopio: R. Antikainen: Oulu: 
New Zealand: C. Anderson: Auckland 
Romania: M. Comsa; Fagaras: D. Dumitrascu; Cluj: D. Jianu; Bucharest: 
Russia: S. Negdogoda; Volgograd: Y. Nikitin; Novosibirsk: 
United Kingdom: C. Rajkumar; London: (Principle Investigator for the ABPM sub-study) 
 
E. Pinto coordinated the ABPM side project and W. Banya was responsible for data 
monitoring and preliminary analyses. 
